RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time g...
Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer...
A large proportion of chronic heart failure (HF) patients are taking suboptimal ...
A meta-analysis has demonstrated consistent efficacy in heart failure outcomes w...
There is a strong opportunity in the heart failure (HF) space for new agents tha...
GlobalData tracks 6 drugs in development for Generalized Pustular Psoriasis (GPP...
GlobalData tracks 119 drugs in development for Frontotemporal Dementia (FTD) by ...
GlobalData tracks 6 drugs in development for Aromatic l-Amino Acid Decarboxylase...
If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option f...
J&J’s BLA was supported by data from the Phase III VIVACITY study, demonstrating...
Alnylam announced positive final results from the Helios-B trial for patients wi...
Experts discuss the relationship between obesity and heart failure while referen...
GlobalData tracks 15 drugs in development for Acute On Chronic Liver Failure (AC...
GlobalData tracks 19 drugs in development for Non-infectious Uveitis by 20 compa...
GlobalData tracks 18 drugs in development for Atypical Teratoid Rhabdoid Tumor b...
Rybrevant has been granted a Type II approval extension to treat NSCLC with EGFR...
